Role and Potential of Different T Helper Cell Subsets in Adoptive Cell Therapy

被引:28
作者
Andreu-Sanz, David [1 ]
Kobold, Sebastian [1 ,2 ,3 ]
机构
[1] Klinikum Univ Munchen, Dept Med 4, Div Clin Pharmacol, LMU Lindwurmstr 2a, D-80337 Munich, Germany
[2] German Canc Consortium DKTK, Partner Site Munich, D-81675 Munich, Germany
[3] Helmholtz Munich, Einheit Klin Pharmakol EKLiP, Res Ctr Environm Hlth HMGU, D-85764 Neuherberg, Germany
基金
欧洲研究理事会; 欧盟地平线“2020”;
关键词
adoptive cell therapy; CD4(+) T cell; immunotherapy; cytokines; TUMOR-INFILTRATING LYMPHOCYTES; RECOMBINANT HUMAN INTERLEUKIN-4; TH9; CELLS; TH17; ANTITUMOR IMMUNITY; DENDRITIC CELLS; HEPATOCELLULAR-CARCINOMA; GENE-THERAPY; IFN-GAMMA; TGF-BETA;
D O I
10.3390/cancers15061650
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary While most cancer immunotherapies have focused on CD8(+) T cells as the main drivers of antitumor immunity, increasing evidence indicates that CD4(+) T cells also play a central role in the elimination of tumors. Naive CD4 T cells can be polarized towards different helper subsets, which can drastically affect the antitumor response through interactions with other cell types and the tumor microenvironment. In this review, we provide an overview of the role of different T helper subsets in the immune system, their implications in cancer immunology, and their applications in adoptive T-cell therapy. Historically, CD8(+) T cells have been considered the most relevant effector cells involved in the immune response against tumors and have therefore been the focus of most cancer immunotherapy approaches. However, CD4(+) T cells and their secreted factors also play a crucial role in the tumor microenvironment and can orchestrate both pro- and antitumoral immune responses. Depending on the cytokine milieu to which they are exposed, CD4(+) T cells can differentiate into several phenotypically different subsets with very divergent effects on tumor progression. In this review, we provide an overview of the current knowledge about the role of the different T helper subsets in the immune system, with special emphasis on their implication in antitumoral immune responses. Furthermore, we also summarize therapeutic applications of each subset and its associated cytokines in the adoptive cell therapy of cancer.
引用
收藏
页数:18
相关论文
共 173 条
[1]   Induction of antigen-specific TH9 immunity accompanied by mast cell activation blocks tumor cell engraftment [J].
Abdul-Wahid, Aws ;
Cydzik, Marzena ;
Prodeus, Aaron ;
Alwash, Mays ;
Stanojcic, Mile ;
Thompson, Megan ;
Huang, Eric H. -B. ;
Shively, John E. ;
Gray-Owen, Scott D. ;
Gariepy, Jean .
INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (04) :841-853
[2]   Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma [J].
Agliardi, Giulia ;
Liuzzi, Anna Rita ;
Hotblack, Alastair ;
De Feo, Donatella ;
Nunez, Nicolas ;
Stowe, Cassandra L. ;
Friebel, Ekaterina ;
Nannini, Francesco ;
Rindlisbacher, Lukas ;
Roberts, Thomas A. ;
Ramasawmy, Rajiv ;
Williams, Iwan P. ;
Siow, Bernard M. ;
Lythgoe, Mark F. ;
Kalber, Tammy L. ;
Quezada, Sergio A. ;
Pule, Martin A. ;
Tugues, Sonia ;
Straathof, Karin ;
Becher, Burkhard .
NATURE COMMUNICATIONS, 2021, 12 (01)
[3]   Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia [J].
Ahearne, Matthew J. ;
Willimott, Shaun ;
Pinon, Lucia ;
Kennedy, D. Benjamin ;
Miall, Fiona ;
Dyer, Martin J. S. ;
Wagner, Simon D. .
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (03) :360-370
[4]   Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions [J].
Alnefaie, Alaa ;
Albogami, Sarah ;
Asiri, Yousif ;
Ahmad, Tanveer ;
Alotaibi, Saqer S. ;
Al-Sanea, Mohammad M. ;
Althobaiti, Hisham .
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2022, 10
[5]   PHASE-I EVALUATION OF THRICE-DAILY INTRAVENOUS BOLUS INTERLEUKIN-4 IN PATIENTS WITH REFRACTORY MALIGNANCY [J].
ATKINS, MB ;
VACHINO, G ;
TILG, HJ ;
KARP, DD ;
ROBERT, NJ ;
KAPPLER, K ;
MIER, JW .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) :1802-1809
[6]   Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System [J].
Avanzi, Mauro P. ;
Yeku, Oladapo ;
Li, Xinghuo ;
Wijewarnasuriya, Dinali P. ;
van Leeuwen, Dayenne G. ;
Cheung, Kenneth ;
Park, Hyebin ;
Purdon, Terence J. ;
Daniyan, Anthony F. ;
Spitzer, Matthew H. ;
Brentjens, Renier J. .
CELL REPORTS, 2018, 23 (07) :2130-2141
[7]  
Azizi G, 2015, EUR ANN ALLERGY CLIN, V47, P108
[8]   The aryl hydrocarbon receptor (AhR) ligand VAF347 selectively acts on monocytes and naive CD4+ Th cells to promote the development of IL-22-secreting Th cells [J].
Baba, Nobuyasu ;
Rubio, Manuel ;
Kenins, Linda ;
Regairaz, Camille ;
Woisetschlager, Maximilian ;
Carballido, Jose M. ;
Sarfati, Marika .
HUMAN IMMUNOLOGY, 2012, 73 (08) :795-800
[9]   Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer [J].
Bindea, Gabriela ;
Mlecnik, Bernhard ;
Tosolini, Marie ;
Kirilovsky, Amos ;
Waldner, Maximilian ;
Obenauf, Anna C. ;
Angell, Helen ;
Fredriksen, Tessa ;
Lafontaine, Lucie ;
Berger, Anne ;
Bruneval, Patrick ;
Fridman, Wolf Herman ;
Becker, Christoph ;
Pages, Franck ;
Speicher, Michael R. ;
Trajanoski, Zlatko ;
Galon, Jerome .
IMMUNITY, 2013, 39 (04) :782-795
[10]   CD4+ T cell help in cancer immunology and immunotherapy [J].
Borst, Jannie ;
Ahrends, Tomasz ;
Babala, Nikolina ;
Melief, Cornelis J. M. ;
Kastenmueller, Wolfgang .
NATURE REVIEWS IMMUNOLOGY, 2018, 18 (10) :635-647